Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer.
Komal L JhaveriMelissa K AccordinoPhilippe L BedardAndres CervantesValentina GambardellaErika Paige HamiltonAntoine ItalianoKevin M KalinskyIan E KropMafalda OliveiraPeter SchmidCristina SauraNicholas C TurnerAndrea VargaSravanthi CheetiStephanie HilzKatherine E HutchinsonYanling JinStephanie Royer-JooUbong PetersNoopur ShankarJennifer L SchutzmanDejan JuricPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Inavolisib plus palbociclib and ET demonstrated a manageable safety profile, lack of DDIs, and promising preliminary antitumor activity.